CD8A and neoplasm: Similarly, targeting the CCL2/CCR2 chemokine pathway – involved in recruitment of monocytes and macrophages – relieves the immunosuppressive phenotype of TAMs and enhances anti-tumor CD8+ T cell responses (134, 135).